PARENTERALE NOROVIRUS-IMPFSTOFFFORMULIERUNGEN
European patent · EP2731621 · In force
Register entry
- Publication number
- EP2731621
- Application number
- EP12811916
- Kind
- European patent with effect for Switzerland and Liechtenstein
- Status
- In force
- Specification
- Granted
- Filed
- Jul 11, 2012
- Published
- May 21, 2014
- Granted
- Nov 1, 2017
- Protection ends at the latest
- Jul 10, 2032
- Next annual fee due
- Jul 31, 2026
- IPC classes
- A61K 39/125 (2006.01)
- Priority
- US 201161506447 P 11.07.2011
- PCT application
- PCT/US2012/046222 11.07.2012
- PCT publication
- WO2013/009849 17.01.2013
- Filing language
- English
- Source
- Swissreg
History
What the Federal Institute of Intellectual Property published about this title, newest first.
- Aug 1, 2025
Change
Published in Swissreg on 01.08.2025
- Aug 1, 2024
Change
Published in Swissreg on 01.08.2024
- Aug 1, 2023
Change
Published in Swissreg on 01.08.2023
- Aug 1, 2022
Change
Published in Swissreg on 01.08.2022
- Sep 22, 2021
Transferred
- Owner
- Takeda Vaccines, Inc., 2155 Analysis Drive, Bozeman, MT 59718, USA → Takeda Vaccines, Inc., 75 Sidney Street, Cambridge, MA 02139, USA
Published in Swissreg on 22.09.2021
- Nov 1, 2017
Granted
Published in Swissreg on 01.11.2017
Parties
Inventor
RICHARDSON, Charles
Bozeman, Montana 59718, US
BARGATZE, Robert, F.
Bozeman, Montana 59718, US
MENDELMAN, Paul, M.
Bozeman, Montana 59718, US
The register names each party by name and address. A holder or agent is linked to an organization where exactly one entity of the commercial register bears its name; the street of a party not so recognised is not shown here.